Enrollment Approximately 50 Percent Complete in Cellceutix Phase 2 Clinical Trial of Prurisol for Chronic Plaque Psoriasis

BEVERLY, MA–(Marketwired – Sept 30, 2015) – Cellceutix Corporation (OTC: CTIX) (the “Company”), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology and antimicrobial applications, today announces that the Company’s Phase 2 clinical trial of the oral drug candidate Prurisol for psoriasis has now enrolled approximately 50 percent of the planned number of patients.  The trial was designed to enroll 100 patients with active mild to moderate chronic plaque psoriasis.  Enrollment is expected to be completed by the end of 2015.

The randomized, double-blind study consists of four arms, with the three active arms receiving different dosing levels of oral Prurisol daily and the fourth arm receiving only placebo daily.  The primary efficacy endpoint will be the percentage of subjects with ≥ 2 point improvement in Investigator’s Global Assessment (IGA) rating as defined by visual inspections of psoriasis lesions over a period of up to 84 days.  More information on the trial is available on the clinicaltrials.gov website at:  https://clinicaltrials.gov/ct2/show/NCT02494479?term=cellceutix&rank=1.

There is an unmet medical need for an effective oral treatment for plaque psoriasis as an alternative to biologic therapies, which currently dominate the market. Cellceutix is very pleased with the steady pace of enrollment in the eight weeks since the trial commenced. To date, no serious adverse events have been reported.

Separately, Cellceutix would like to inform shareholders that approximately 30 pounds of the active pharmaceutical ingredient (API) in Brilacidin has been manufactured. The API will soon begin formulation for use in the planned clinical trials of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and other indications.